Fibrinolysis
8
1
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
12.5%
1 terminated out of 8 trials
85.7%
-0.8% vs benchmark
38%
3 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Genetic Variants of Annexin A2 and Cryptogenic Stroke
Anti-fibrinolytic and Anti-inflammatory Effects of Local Infiltration of Tranexamic Acid in Patients With Calcaneal Fractures
Fibrin Clot Properties and Blood Loss Following Coronary Artery By-pass Grafting
Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis
Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass
The RAS, Fibrinolysis and Cardiopulmonary Bypass
EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye